In the traditional medical device development model, regulatory strategy and manufacturing are often treated independently. A founder might hire a regulatory consultant to map out a 510(k) pathway while simultaneously searching for a contract manufacturer to build prototypes.
At Kapstone Medical, we've seen this fragmentation derail otherwise promising programs. The FDA clears a device based on performance data, and that data must remain valid once the product moves to full-scale production. When regulatory strategy is disconnected from the production floor, you risk earning a clearance that simply cannot survive the realities of commercial scaling. That can mean re-validation, unexpected costs, delayed revenue, or worst case, new regulatory submissions if manufacturing changes impact the device’s safety or efficacy.
By involving manufacturing leadership in early strategic sessions, we ensure that every claim made in a submission is backed by a manufacturing process that takes into consideration the potential regulatory impacts of volume scaling.
A 510(k) submission proves that a device is substantially equivalent to a predicate. While the 510(k) document itself does not typically include full process validation reports, the final commercialized device still depends on the production floor processes for conformance to the 510(k) based specifications. Think of it this way: the 510(k) is your argument to the FDA, and your production floor is your evidence. If the two don't align, the argument falls apart.
The FDA requires that V&V testing be performed on "production-equivalent" units. If the processes used to create those samples—such as machining, sterilization, or packaging—change significantly during the transition to mass production, the original test data may no longer support the device.
One of the most expensive and avoidable mistakes we see startups make is accumulating what we call "Safety Debt." It happens gradually: a device is cleared using lab-scale or low-volume processes that were never truly designed for high-volume production. The clearance looks like a win. Then the scale-up begins.
When companies discover that their submission-level manufacturing can't be replicated cost-effectively at volume, they're forced into re-validation. Changing a manufacturing method, even a seemingly minor one, often triggers new testing requirements to demonstrate that the change hasn't negatively impacted device performance or safety. The testing alone can set a program back months.
To mitigate this, our operational and regulatory teams ensure the device is manufacturable before formal V&V testing begins. We "lock in" the regulatory and production paths simultaneously.
The transition to the Quality Management System Regulation has heightened the focus on how OEMs and contract manufacturers communicate, and for many teams it remains one of the most misunderstood intersections in the regulatory landscape. If you want to go deeper on this topic, our guide to Navigating Medical Device Design Transfer Under the New QMSR is a useful starting point.
Directly, no. The 510(k) is a pre-market requirement, while the QMSR governs post-market quality and manufacturing. However, the two are linked by Design Transfer. The QMSR requires a robust integration of quality records, and whether you are an individual inventor or a mid-sized OEM, our unified quality environment ensures that your production records, the foundational proof of your device's history, are always inspection ready.
Getting a 510(k) clearance is a significant achievement, but it is only the beginning. The real test is whether the device you cleared is the device you can consistently manufacture at scale, on time, and within budget. Programs that treat regulatory strategy and manufacturing as separate workstreams often find out the hard way that a clearance built on shaky production foundations creates more problems than it solves.
At Kapstone Medical and Kapstone Manufacturing, we built our model around eliminating that gap. Our regulatory and manufacturing teams work side by side from your earliest concept discussions through commercial launch. There are no handoffs between siloed departments, no last-minute surprises when prototype processes don't translate to the floor, and no scrambling to re-validate because the submission and the production reality were never aligned in the first place.
If you are mapping out your path to market, or if you are already in development and starting to feel the friction of fragmented strategy, we would welcome the conversation. Reach out to our team to learn how Kapstone's integrated approach can get your device to market faster, with fewer detours along the way.
Ideally, during the Concept Phase. Early involvement allows us to identify material or process risks that could complicate the 510(k) submission or impact long-term scalability.
An MVP is a high-level document that outlines which processes (such as cleaning, sterile packaging, or laser welding) must undergo IQ/OQ/PQ. At Kapstone, we co-author this across our regulatory and manufacturing teams to ensure the strategy for validation supports the claims made to the FDA.
It is highly discouraged. The FDA expects submission data to be representative of the final production device. Using data from a non-regulated environment creates a "gap" that can lead to rejections or the need to repeat expensive testing.